



IN-FAQ BY JOY BHATTACHARJYA

On this day in 1945, General Alfred Jodl, the last Nazi military commander, signed an unconditional surrender, ending Germany's participation in the Second World War. This week's quiz is all about "lasts".

Questions

- Whose last actions on his most famous expedition was to carve his daughter Tracy's initials, TDC in the dust?
- On 7 September 1936, Benjamin died from exposure at the Beaumaris zoo. He was the last known specimen of which species?
- The first ever century before lunch in a test match was recorded by Victor Trumper. Who scored the last?
- What was the name of the last song recorded collectively by all four Beatles?
- On March 19th, 1989, in Indian Wells, tennis player Miloslav Mecir became the last person to do what?
- If Reita Faria was the first in 1966, who was the last, around five years ago?
- The Last King of Scotland, a novel by journalist Giles Foden, later made into an acclaimed film, is based on which real life historical character?
- A first in a 'last.' Who made his debut in the 1969 film Akhree Khat?
- Sourav Ganguly and Rahul Dravid's debut test match was the last test for which stalwart of the game?
- Last lines of which famous work. "The creatures outside looked from pig to man, and from man to pig, and from pig to man again; but already it was impossible to say which was which."

Answers

- Eugene Cernan, the last man to step on the moon
- Tasmanian Tiger
- Shikhar Dhawan
- Appropriately enough, The End
- Win an ATP tournament with a wooden racket
- Manushi Chhillar, Indian Miss World
- Idi Amin of Uganda
- Rajesh Khanna
- Dickie Bird
- Animal Farm, by George Orwell

JOY BHATTACHARJYA is a quiz master; joybhattacharjya@gmail.com

USFDA restricts J&J's Covid vaccine due to blood-clot risk

ASSOCIATED PRESS

US regulators have strictly limited who can receive Johnson & Johnson's Covid vaccine due to the ongoing risk of rare but serious blood clots.

The FDA said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J's vaccine. For months US authorities have recommended that Americans get Pfizer or Moderna shots instead of J&J's vaccine.

FDA's vaccine chief Peter Marks said the agency decided to restrict the vaccine after taking another look at the data on

the risks of life-threatening blood clots and concluding that they are limited to J&J's vaccine.

"If there's an alternative that appears to be equally effective in preventing severe outcomes from Covid, we'd rather see people opting for that," said Marks. "But we've been careful to say that - compared to no vaccine - this is still a better option." The problem occurs in the first two weeks after vaccination, he added. "So, if you had the vaccine six months ago, you can sleep soundly tonight, knowing this isn't an issue." The FDA authorised J&J's shot in February last year for adults 18 and up.

Govt to keep tabs on Chinese investments in Indian firms

Makes it mandatory for entities to get government approval before investing

SHISHIR SINHA

New Delhi, May 6

The Corporate Affairs Ministry has notified changes in rules to keep a check on Chinese firms investing in Indian companies.

A consequence of Press Note-3 (PN-3) on changes in foreign investment norms and to ensure strict compliance, it is seen as having larger implications.

PN-3 prescribes that an entity of a country, which shares land border with India or where the beneficial owner of an investment into India is situated in or is a citizen of any such country, can invest only through the government route. This provision was inserted mainly to curb Chinese investment in India.

According to the Gazette Notification, a proviso has been added to Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014. It says: "No offer or invitation

of any securities under this rule shall be made to a body corporate incorporated in, or a national of, a country which shares a land border with India, unless such body corporate or the national, as the case may be, has obtained government approval under the Foreign Exchange Management (Non-debt Instruments) Rules, 2019 and attached the same with the private placement offer-cum application letter." Also, the applicant will have to clarify whether or not it requires government approval.

Expert views

Ashish Kumar Singh, Managing Partner of Capstone Legal, said India has a high volume of commercial interaction with China, and it seems the government wants to keep an eye on Chinese entities making inroads into the Indian market. "The Companies Act gives the government wide powers to frame rules un-



der Section 469 and, if necessary, it may also invoke penal provisions to enforce these rules," he said.

Sriram Ramachandran, Partner, Phoenix Legal, said post-amendment to the rules, a copy of approval (government), where applicable, is required to be filed along with PAS 4 (the form) by the company proposing to receive any foreign investment.

Key factors

According to Manish Gupta, partner with IndusLaw, these changes, along with share capital and debenture rules, bring in a few interesting things. First, the government has made it mandatory for foreign

investors to make a positive statement to the investee Indian company that it is entitled to acquire shares, either through primary or secondary route without requiring any government approval. But, more importantly, the scope here is not limited to investors from the land bordering countries or issues related to PN-3.

Second, it makes it mandatory for the Indian company to ensure that the foreign investor is not incorporated in, or is not a national of, a land-bordering country, but does not talk about the wide and vague concept of beneficial ownership as provided in the PN-3.

However, same is not the case with positive confirmation to be made by the foreign investors as the scope is not limited but covers the entire NDI (non-debt instrument) rules.

"Third, this has reaffirmed the government's position and the general market notion that PN-3 will continue for a longer period and is not a temporary measure," said Gupta.

WHO REPORT ON COVID DEATHS

Experts divided on the veracity of report

PT JYOTHI DATTA

Mumbai, May 6

The World Health Organization's report on excess deaths due to Covid has stirred a hornet's nest in India, with doctors and health administrators contesting the gap between India's reported death toll and that projected by the report.

India is projected to have witnessed 47 lakh deaths due to Covid, the report said, almost 10 times the reported deaths at 4.8 lakh up to December 2021.

The gap should be seen as a "symptom of the lack of a system" to capture the public health details behind a death, said veteran virologist Jacob John. "The truth is more towards the WHO side than the government numbers," John told *BusinessLine*, adding that it was not India's fault, and there was no intention to be "dishonest".

"There is no public health system in the country to capture details on the death by disease or diagnosis, as it was never demanded," he said, pointing out that he had been



India is projected to have witnessed 47 lakh deaths due to Covid, according to the WHO report

advocating for such a system for the last 30 years.

The latest report is "a signal on the need to create such a system", he said, pointing to agencies in the UK and the US that capture granular data and the disease event behind the statistic.

Civil registries merely capture the civil data, he said, and not the public health event behind the death. And even though health administrators say they have captured granular details during Covid, John

said it has not been verified in terms of the disease event behind the death.

Flawed projection

Dissecting the WHO statistics, Rajeev Jayadevan, Co-Chairman National IMA Covid Task Force, points out it was "impossible that 8.9 out of 10 deaths from Covid were missed in a country like India", which has robust systems in place. Even in the best of countries, it is accepted there will be under-counting for various reasons, he said. But

a gap of 9.9x, he said, was off the mark.

Death reporting varies across villages in a single State, depending on the prevailing public health systems available, he said, indicating that it was flawed to project numbers from the experience of one region across multiple locations. Some regions may have been more severely affected than others, he said, indicating that it was erroneous to "generalise from the extreme".

Meanwhile, the WHO report added a technical note for India, saying: "These estimates may not be regarded as the national statistics officially produced by India due to differences arising from the data and methods used by WHO. The information from the Civil Registration System in India for 2020 was made publicly available by the Registrar General of India on 3 May 2022... The newly published information in the report is being carefully examined, and will be taken into consideration in revisions of the estimates."

Amour-a Tumhara Cinema!



Amul
Celebration of our culture!

India ready to challenge WHO on Covid-19 data

BJP, Opposition parties engage in war-of-words over death rate



AM JIGEEESH

ABHISHEK LAWL

New Delhi, May 6

India is ready to challenge the World Health Organization (WHO) report on excess mortality count due to Covid, focusing on the anomalies in the numbers, said sources.

The Union Health Ministry has objected to the WHO's sourcing of data, methodology for collecting data, and the mathematical model that was used for arriving at the final figures.

Objections have also been raised regarding the fact that India is being listed in Tier-2 countries, despite it being open to sharing data with the WHO. "India is ready to challenge the report, and rightly so," the source told *BusinessLine*.

Meanwhile, the ruling BJP and the Opposition parties have engaged in a war-of-words over the report. While the BJP said the Opposition is politicising the issue, the Opposition parties said the Centre lied to people on the death count.

India's objections

"WHO has released the excess mortality estimates without adequately addressing India's concerns," said a government statement released on Thursday.

The statement by the Ministry said India had informed the WHO that in view of the

availability of authentic data published through Civil Registration System (CRS) by Registrar General of India (RGI), mathematical models should not be used for projecting excess mortality numbers.

India has also questioned the WHO's use of data for 17 States, obtained from some websites and media reports, for the mathematical model.

"This reflects a statistically unsound and scientifically questionable methodology of data collection for making excess mortality projections in case of India," said its statement, adding that "WHO has projected different excess mortality figures for India citing multiple models, which itself raises questions on the validity and robustness of the models used".

Congress leader Rahul Gandhi said 47 lakh Indians died due to the Covid pandemic, not 4.8 lakh, as claimed by the Centre. "Science doesn't lie. (Prime Minister Narendra) Modi does," he said on Twitter.

CPI(M) General Secretary Sitaram Yechury said the figures are damning.

"Pay the mandatory compensation to the agonised families who lost their loved ones," he wrote on Twitter.

On Day 2 of Goafest, Zee gets highest tally of metals in Broadcaster ABBY

OUR BUREAU

Goa, May 6

Day two of Goafest 2022, the advertising, marketing and media industry's biggest event that celebrates creativity, culminated with ABBY Awards being given out in nine categories. These included Broadcaster ABBY, Technology ABBY, Design ABBY, and Digital ABBY, among others.

Sony Pictures Networks India and TV18 Broadcast saw strong wins in the Broadcaster ABBY. The two broadcasters bagged two golds - Sony for the best TV sports channel promo for its Love for Cricket campaign and for its UEFA Champions League Sona Mana Hai campaign.

At the same time Zee ended up with the highest tally of 13 metals in the broadcasters category, with Zee Kannada picking up a gold for the best launch of a TV channel.

In the Technology ABBY, Samsung won a gold for best creative use of tech in-

novation for its Goodvibes campaign created by Cheil. Sangbad Pratidin won a gold and silver for its #MaaClicks - No Selfie this Puja campaign, which won the best use of technology for community management/building and second spot in best creative use of tech innovation. Amazon Prime Video also picked up two metals.

Lone gold award winner Burger King was the lone gold award winner in the Digital ABBY segment for its social-media work, #LonelyNoMore, created by Famous Innovations. It also bagged the highest metals in this category.

In the Mobile Abby category, Cheil India bagged four metals, including a gold, for its work for Samsung.

The first day saw Mindshare picking up the 'Agency of the year' award and bagging eight gold metals. Lodestar UM won the Grand Prix. The second

day saw a bevy of distinguished guests addressing the attendees. These included two-time Olympic medallist PV Sindhu and former cricketer Kapil Dev, besides Menno Kluin, Chief Creative Officer, Dentsu Creative USA.

Union Minister Hardeep Singh Puri and film director SS Rajamouli also took the stage in knowledge sessions at the festival.

PV Sindhu spoke about the importance of celebrities to know and understand what the brand is about before putting their name behind it. She talked about the success mantra and coping mechanism to deal with a loss in a match.

Rajamouli, who has emerged as one of the most successful film directors in recent times, gave advice on dealing with failure. Re-counting his own failures in getting his ideas to the screen, he spoke on how failure can be a learning experience on one's journey.

China hits back at 'zero Covid' policy doubters

REUTERS

Beijing, May 6

Residents of Beijing fretted on Friday over dozens of new Covid cases reported daily and over the possibility of more restrictions on movements as China's leaders threatened action against critics of their zero-Covid policy.

Incurring a heavy economic cost and facing rare public cri-

ticism on its tightly controlled Internet, China is increasingly out of step with the rest of the world where Covid restrictions are being abandoned and vaccines relied on to protect people.

After a meeting of the highest decision-making body, the Standing Committee of the Communist Party's politburo, state media reported

late on Thursday that China would fight any comment or action that distorted, doubted or repudiated its Covid policy.

Relaxing Covid controls, which were being imposed in dozens of cities across the world's second-largest economy and affecting hundreds of millions of people, would lead to large-scale infections, it warned.

Sundaram-Clayton Limited

Regd office: "Chaitanya", No.12, Khader Nawaz Khan Road, Nungambakkam, Chennai 600 006.

Tel : 044-2833 2115 Fax : 044 - 2833 2113

Website : www.sundaram-clayton.com Email : corpsec@sundaramclayton.com

CIN : L35999TN1962PLC004792

STATEMENT OF FINANCIAL RESULTS
FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2022

(Rs. in Crores)

S. No	Particulars	Standalone			Consolidated		
		Quarter ended	Year ended	Quarter ended	Quarter ended	Year ended	Quarter ended
		31.03.2022	31.03.2021	31.03.2022	31.03.2022	31.03.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Total Income	589.99	503.71	1,836.86	6,915.91	6,451.09	25,625.15
2	Net Profit / (Loss) before tax (before Exceptional Items)	124.45	130.00	177.89	404.82	455.14	1,196.15
3	Net Profit / (Loss) before tax (after Exceptional Items)	735.89	127.77	2,300.49	414.64	446.71	1,184.20
4	Net Profit / (Loss) after tax (after Exceptional Items)	722.24	82.85	2,276.69	308.00	307.34	824.49
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax)]	720.22	129.13	2,273.57	324.68	390.82	824.30
6	Equity share Capital (Face value of Rs.5/- each)	10.12	10.12	10.12	10.12	10.12	10.12
7	Reserves (excluding Revaluation Reserve)	-	-	2,890.24	-	-	5,069.12
8	Security Premium Account	36.42	36.42	36.42	36.42	36.42	36.42
9	Networth	2,893.66	556.27	2,893.66	5,015.06	2,679.66	5,015.06
10	Outstanding Debt (Excluding NBFC Subsidiary)	732.64	631.23	732.64	3,065.81	2,407.22	3,065.81
11	Outstanding redeemable Preference Shares	- NOT APPLICABLE -					
12	Debt Equity Ratio (including exceptional item)	0.25	0.85	0.25	2.00	2.35	2.00
13	Earnings Per Share (Face value of Rs.5/- each) (not annualised) (In Rs.)						
	(i) Basic	356.98	40.95	1,125.29	80.81	82.62	217.84
	(ii) Diluted	356.98	40.95	1,125.29	80.81	82.62	217.84
14	Capital Redemption Reserve	- NOT APPLICABLE -					
15	Debenture Redemption Reserve	- NOT APPLICABLE -					
16	Debt Service Coverage Ratio (Excluding NBFC Subsidiary)	2.87	1.38	1.97	6.04	9.19	5.61
17	Interest Service Coverage Ratio (Excluding NBFC Subsidiary)	14.29	16.95	7.57	15.84	11.83	12.56

Notes :

- The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulations 33 & 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Stock exchanges websites (www.bseindia.com and www.nseindia.com) and on Company's website (www.sundaram-clayton.com).
- The Company has prepared these standalone and consolidated financial results in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IndAS) prescribed under Section 133 of the Companies Act, 2013.
- Earnings Per Share (EPS) of Rs. 1,125.29 for the year ended 31.03.2022 and Rs.356.98 for the quarter ended 31.03.2022, as given above is after including the exceptional income of Rs. 2,142.35 Crores and Rs.617.03 Crores. Excluding the exceptional income, EPS for the year ended 31.03.2022 is Rs. 66.39 and Rs.52.00 for the quarter ended 31.03.2022.

For Sundaram-Clayton Limited

Date : 6th May 2022

R.Gopalan
Chairman

CORONA METER

CASES ON FRIDAY

2,005⁺

ACTIVE CASES

20,094(+333)^o

Recovered

42.55 m (+1,670)

Deaths

524,004 (+2)

TOTAL CASES

43,096,912

Source: State Bulletin, PTI. *13 states/UTs (incl. West & UP as of 6:00 PM. Net of recoveries/ deaths change since 12am, 06 May)

4 Main Metros

CASES ON FRI

ACTIVE CASES

Delhi

1656

6096

B'uru Urban

123

1789

Mumbai

117

706

Chennai

34

300^{*}

Source: State Bulletin, PTI

VACCINE DOSES ADMINISTERED IN INDIA

1900.32 M(+1.65 m)

1st dose...

1005.20 m (92.72%)

2nd dose

865.81 m (79.86%)

IS 12m+ population

BOOSTER DOSES

TOTAL 29.31 m

Source: dashboard.covidgov.in, 06:00 PM

GLOBAL COUNT

Total Cases

515.97 M

Deaths

6,272,484

Recovered

470.80 M

Source: worldometers.info, 08:00 PM

Vaccine Doses Administered

11698.85 Million

(304 countries/areas)

NEW INFECTIONS IN 5 WORST-HIT COUNTRIES*

Germany

87201

USA

66611

Australia

54868

Italy

48255

France

44225

*as of Thu

FMCG Cos Expect Rural Demand to Recover by Second Quarter

Good monsoon forecast, higher capex and govt schemes to help revive consumption

Ratna Bhushan & Sagar Malviya

New Delhi | Mumbai: Packaged consumer goods companies' chief executives said they expect rural demand which slowed down over the past two quarters, to recover by the second quarter of the financial year, on the back of good monsoon forecasts, higher capital investments and additional outlays in government schemes such as the Mahatma Gandhi National Rural Employment Act. "We believe the slowdown in rural markets is temporary and should get corrected by end of the June quarter, or at most second quarter," said Mohit Malhotra, chief executive of Dabur for which rural markets contribute 47% of its overall sales. "We expect easing of liquidity pressures, and a combination of factors such as a good harvest, better than

normal monsoon forecast and additional outlays announced by the government to contribute to rural revival," Malhotra said, adding that the company, which makes Vatika shampoo and Real juice, will continue to invest ahead of the curve in expanding its rural coverage. India's villages, which contribute around 35% of overall FMCG sector sales, saw growth declining since September last year as steep inflation of food, other daily essentials and fuel, and declining wages forced consumers to either downgrade (or buy cheaper products), or stop buying these products. Sanjiv Mehta, managing director at the country's largest consumer goods maker Hindustan Unilever, said there are a few factors that could contribute to rural recovery. "First is a good harvest. We are seeing that the rabi harvest should be good on all counts. Second, the indi-

Higher Hopes

KEY TRIGGERS

Additional outlays in govt job schemes

Easing of liquidity pressures

Return of jobs for daily wagers

WHAT COS ARE DOING

Doubling down on distribution expansion in villages

Top FMCG cos added nearly 40 direct distributors every day since pandemic

RURAL INDIA: Contributes around 35% of FMCG sales

cators are that the rainfall should be decent. The third is with the agri prices moving up, there would be benefit to the farmers," Mehta said at an earnings call last week. "The government spending of ₹75 lakh crore on capital expenditure, if that is front-ended, which I believe it should be, then we should start seeing a recovery happen," he added. According to research firm Kantar, rural demand is still growing compared

to that of the urban market, which fell 3.4% during March quarter. However, rural growth has tapered off to 1.7% last quarter compared to 2.7% a year ago. Edible oils maker Adani Wilmar MD Angshu Mallick told ET he expects rural demand to revive by the second quarter. "Apart from a good monsoon prediction, there are all indications that commodity inflation will decline. Another reason is, that many villagers who had lost their jobs have returned to cities and been re-employed — they are resuming sending back money to their households in villages, which will improve purchasing power," Mallick said. The company, he added, is on track with its go-to-market strategy focused to capture rural growth.

AMSTRAD

KHUSHIYON KI SHURUAAT

It's YOUR Money. Spend it WISELY.

10% Cashback

FEDERAL BANK

Powered by pine labs

Ford Assures Chennai Plant Workers about Clarity over Future After Sit-in

Workers voiced their concern after the American carmaker announced its exit from the country

Bharani V & Dia Rekhi

Chennai: Workers at Ford India's plant near Chennai withdrew a sit-in protest on Friday after the company gave an assurance that it would update them about the future of their jobs as well as plans to turn one of its India factories into an electric vehicles (EVs) manufacturing hub. The workers at the 350-acre unit took up the demonstration late on Thursday demanding clarity over their future after the American carmaker said last year that it would cease operating in the country due to mounting losses. "Workers in large numbers decided to stage a demonstration because we wanted answers. They've now told us they would give us an update soon. We've called off the protest," said a Ford India plant worker and a Union representative



who did not wish to be named. Ford is likely to provide an update on jobs at its factory and its EV plans early next week, a state government official told ET. Factory workers had earlier remained hopeful after Ford said it would consider converting one of its India plants into an EV hub. The company has another plant in Sanand (Gujarat), located next to the Tata Motors factory. The workers had been waiting for several weeks to receive answers from the company management on whether the Chennai plant would be turned into an EV hub, before beginning the sit-in protest around 3:30 pm on Thursday. The Tamil Nadu government's la-

CLARITY NEXT WEEK
Ford is likely to provide an update on jobs at its factory and its EV plans early next week

bour department had, meanwhile, been holding discussions with the Ford management and workers, encouraging them to find an amicable solution. "We've advised the management and the workers' union to engage in a dialogue over the future of jobs at the plant," a state government official directly aware of reconcil-

iation talks had said. Industries minister Thangam Thennarasu told ET that the state government was also in talks with Ford on winding up its operations as well as associated matters, and the need for a "quick decision." A Ford spokesperson told ET: "We continue to remain engaged with our employees and union representatives on all outstanding matters including compensation and have nothing further to add or share at this point." The company said there would be no loss of jobs. "We remain committed to fairly supporting those directly impacted by the restructuring and continue to explore possible alternatives for our manufacturing facilities," the spokesperson added. In September last year, Ford said it would exit India and cease assembly for the domestic market due to its \$2 billion accumulated losses. However, in February this year, Ford qualified for a key central government incentive scheme for EVs, along with other players such as Hyundai. Any decision by the company to convert one of its India plants exclusively to make EVs is being closely watched by the industry as well as the concerned state governments.

GENERIC VERSION COULD BE LAUNCHED SOON 'No Merit Seen in Including Paxlovid in Covid Treatment'

Data from trials of the Pfizer drug awaited and will be reviewed later, say experts

Teena Thacker
@timesgroup.com

New Delhi: Pfizer's antiviral drug Paxlovid has not found its way into the national treatment guidelines for Covid-19 yet. In a meeting held last week, the experts at the Indian Council of Medical Research's (ICMR) National Task Force on Covid-19 did not find merit in its inclusion, said Samiran Panda, head of epidemiology and infectious diseases at the Indian Council Medical Research (ICMR).

"The current evidence did not merit inclusion of Paxlovid in the treatment guidelines and the existing guidelines stand valid," he said, adding that the experts are awaiting data from ongoing trials and will review it further as data comes. "As of now the current evidence doesn't support its inclusion. But there are trials which are underway and we are waiting for more data and will review it again," Panda told ET. Antiviral drug Molnupiravir, earlier failed to convince the ICMR for its inclusion in India's national Covid-19 treatment protocol due to 'safety concerns', even as it received an emergency use authorization (EUA) from the drug regulator. India's drug regulator approved Paxlovid for restricted emergen-

Wait Time

Hyderabad's Hetero Labs to manufacture generic version of Pfizer's drug

Price being worked out

Drug "strongly recommended" by the WHO

cy use against Covid-19 last month, amid rising infections in the country. Hyderabad-based Hetero Labs will manufacture the generic version of Pfizer's drug, touted as a game changer in the fight against the disease. The generic version of the drug is likely to be launched soon by Hyderabad-based Hetero Labs. It is working on the price of the pill, people in the know earlier told ET. The drug has been "strongly recommended" by the World Health Organization (WHO) in patients with mild and moderate forms of coronavirus disease (Covid-19) at the highest risk of hospitalisation. The recommendation is based on data from two randomised controlled trials showing that the risk of hospital admission is reduced by 85% following the administration of the drug in a high-risk group. The UN agency has, however, recommended against its use in Covid patients at lower risk of hospitalisation, stating the benefits were found to be negligible.

'Some Rapid Tests may be Less Sensitive to Covid-19 Variants'

BOSTON: While the rapid antigen tests remain a useful tool for the detection of Covid-19 infections, some of these diagnostic kits may be less sensitive to the variants of concern, according to a US study. Scientists at the Harvard TH Chan School of Public Health and Beth Israel Deaconess Medical Center in the US noted that the rapid tests were developed for use with the original SARS-CoV-2 viral strain that emerged late in 2019. In the study published in the Journal of Clinical Microbiology, the researchers used live virus culture to assess how well 4 rapid tests are able to detect these Covid variants of concern. "Unlike sensitive molecular tests that detect multiple SARS-CoV-2 genes, rapid antigen tests target a single viral protein," said study co-corresponding author James Kirby. "As the pandemic continues, however, some hypothesis that the performance of available antigen test may vary among the COVID variants of concern," Kirby said in a statement. Using three

strains of cultured live virus, the team assessed differences in the limits of detection (LoD) — the smallest amount of viral antigen detectable at 95 per cent certainty — of four commercially available rapid antigen tests; the Binax, CareStart, GenBody and LumiraDx tests. The researchers found that all four tests were as sensitive to the Omicron variant, if not more, as they were to original SARS-CoV-2 viral strain, known as WAI. However, three tests showed less sensitivity to the Delta strain, with only the CareStart demonstrating equal detection of all three strains, they said. "We expect that the observed loss in Delta sensitivity could have resulted in a 20 per cent or more loss of detection in potentially infectious individuals — nevertheless, the most infectious individuals still should have been detected," said Kirby, also a professor of pathology at Harvard Medical School. PTI.

Sundaram-Clayton Limited

Regd office: "Chaitanya", No.12, Khader Nawaz Khan Road, Nungambakkam, Chennai 600 006.
Tel : 044-2833 2115 Fax : 044 - 2833 2113
Website : www.sundaram-clayton.com Email : corpsec@sundaramclayton.com
CIN : L35999TN1962PLC004792

STATEMENT OF FINANCIAL RESULTS

FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2022

(Rs. in Crores)

S. No	Particulars	Standalone		Consolidated	
		Quarter ended	Year ended	Quarter ended	Year ended
		31.03.2022	31.03.2022	31.03.2022	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income	589.99	503.71	6,915.91	6,451.09
2	Net Profit / (Loss) before tax (before Exceptional Items)	124.45	130.00	404.82	455.14
3	Net Profit / (Loss) before tax (after Exceptional Items)	735.89	127.77	2,300.49	414.64
4	Net Profit / (Loss) after tax (after Exceptional Items)	722.24	82.85	2,276.69	308.00
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income / (Loss) (after tax))	720.22	129.13	2,273.57	324.68
6	Equity share Capital (Face value of Rs.5/- each)	10.12	10.12	10.12	10.12
7	Reserves (excluding Revaluation Reserve)	-	-	2,890.24	-
8	Security Premium Account	36.42	36.42	36.42	36.42
9	Networth	2,893.66	556.27	2,893.66	5,015.06
10	Outstanding Debt (Excluding NBFC Subsidiary)	732.64	631.23	732.64	3,065.61
11	Outstanding redeemable Preference Shares	- NOT APPLICABLE -			
12	Debt Equity Ratio (including exceptional item)	0.25	0.85	0.25	2.00
13	Earnings Per Share (Face value of Rs.5/- each) (not annualised) (In Rs.)				
	(i) Basic	356.98	40.95	1,125.29	80.81
	(ii) Diluted	356.98	40.95	1,125.29	80.81
14	Capital Redemption Reserve	- NOT APPLICABLE -			
15	Debt Redemption Reserve	- NOT APPLICABLE -			
16	Debt Service Coverage Ratio (Excluding NBFC Subsidiary)	2.87	1.38	1.97	6.04
17	Interest Service Coverage Ratio (Excluding NBFC Subsidiary)	14.29	16.95	7.57	15.84

Notes:

1 The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulations 33 & 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Stock exchanges websites (www.bseindia.com and www.nseindia.com) and on Company's website (www.sundaram-clayton.com).

2 The Company has prepared these standalone and consolidated financial results in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IndAS) prescribed under Section 133 of the Companies Act, 2013.

3 Earnings Per Share (EPS) of Rs. 1,125.29 for the year ended 31.03.2022 and Rs.356.98 for the quarter ended 31.03.2022, as given above is after including the exceptional income of Rs. 2,142.35 Crores and Rs.617.03 Crores. Excluding the exceptional income, EPS for the year ended 31.03.2022 is Rs. 66.39 and Rs.52.00 for the quarter ended 31.03.2022.

For Sundaram-Clayton Limited

R.Gopalan
Chairman

Date : 6th May 2022

Fresh to home

FRESH OR FREE

If Your Order Isn't 100% Fresh, We'll Give Your Money Back.

Goat (Curry cut) 500g

Chicken (Curry cut) 500g

Prawns (Small, Cleaned) 250g

Code: 599GCP

₹599*

Baasa Fillet (Boneless) 500g

Mathi/ Sardine 500g

Mackerel Fish Cutlets Pack of 3

'275'

'145'

'99'

100+ Quality Checks

Vacuum Sealed For Freshness

Sourced From Dedicated Farmers & Fishermen

No Anti-biotic Residue

No Added Chemicals

We deliver in: Bangalore | Mangalore | Mysore | Mandya | Nagamangala | Tumkur | Sakleshpur | Hassan | Chikmagalur

Order online at: Freshtohome.com

90 Minute Delivery

*T&C Apply: All prices are inclusive of taxes. Offers valid only for today and till stocks last.
*T&C Apply: Money back will be credited as FreshCash. Refer website for more details. Images used are for representative purposes only and may differ from the actual products. FreshToHome is only a brand name or trade mark and does not represent its true nature.